Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

When there are higher than normal amounts of HER2 on breast cancer cells, the cancer is called HER2 positive. And these cancer cells can grow more rapidly than other breast cancers. HER2 positive ...

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

The peritoneal cavity, which contains the abdominal organs, is a less common but still potential site for breast cancer to ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

When you have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on managing your disease, not curing the cancer. The goal is to help you live longer and have a better ...